Company / Accounts Receivable
Cue Biopharma, Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$5.5M
FY2025
5-year range
$57.0K / $5.5M
FY2021-FY2025
Trend
+486.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable changed +487% YoY in FY2025, a notable deviation from the 6-year average annual change of +572%.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +31.4%.
Improved from $2M to $6M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +359.9%
- 5-Year CAGR
- +31.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +31.4%, indicating consistent growth.
- In FY2025, accounts receivable increased 486.9% year-over-year.
- Lowest accounts receivable in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.5M | +486.9% |
| FY2024 | $945.0K | -44.3% |
| FY2023 | $1.7M | +2878.9% |
| FY2022 | $57.0K | -98.2% |
| FY2021 | $3.1M | +121.7% |
| FY2020 | $1.4M | +87.8% |
| FY2019 | $754.9K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026